


RealRate

## PHARMACEUTICAL 2022



## UNITED THERAPEUTICS Corp Rank 26 of 475





## PHARMACEUTICAL 2022





## **UNITED THERAPEUTICS Corp** Rank 26 of 475

The relative strengths and weaknesses of UNITED THERAPEUTICS Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UNITED THERAPEUTICS Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 289% points. The greatest weakness of UNITED THERAPEUTICS Corp is the variable Other Expenses, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 197%, being 473% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	2,323,600
Cost of Goods Sold	122,500
Intangible Assets	0
Liabilities, Current	305,400
Liabilities, Non-Current	104,800
Other Assets	2,064,600
Other Compr. Net Income	-8,800
Other Expenses	585,100
Other Liabilities	800,000
Other Net Income	38,000
Property and Equipment	780,900
Research and Development	540,100
Revenues	1,685,500
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	5,169,100
Liabilities	1,210,200
Expenses	1,247,700
Stockholders Equity	3,958,900
Net Income	475,800
Comprehensive Net Income	471,400
Economic Capital Ratio	197%